Journal
MOLECULAR CANCER THERAPEUTICS
Volume 20, Issue 6, Pages 1102-1111Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-20-0944
Keywords
-
Categories
Funding
- NIH [U01-DE029759, RO1 CA172886, RO1 GM58670]
- Leopoldina Fellowships from German National Academy of Sciences Leopoldina [LPDS 2017-12, LPDR 2019-02]
- Freier Verband Deutscher Zahnarzte e.V. (FVDZ)
- European Union's Horizon 2020 research and innovation programme under the Marie Skoodowska-Curie grant [893196]
Ask authors/readers for more resources
This study found that two novel TGF beta inhibitors can reduce tumor burden and decrease body weight loss in a murine oral squamous cell carcinoma (OSCC) model, and enhance CD8(+) T-cell infiltration into tumors. Combination therapy with PD-L1 antibodies further reduces weight loss and accelerates lymphocyte infiltration into tumor tissues.
TGF beta is a key regulator of oral squamous cell carcinoma (OSCC) progression, and its potential role as a therapeutic target has been investigated with a limited success. This study evaluates two novel TGF beta inhibitors as mono or combinatorial therapy with anti-PD-L1 antibodies (alpha-PD-L1 Ab) in a murine OSCC model. Immunocompetent C57BL/6 mice bearing malignant oral lesions induced by 4-nitroquinoline 1-oxide (4-NQO) were treated for 4 weeks with TGF beta inhibitors mRER (i.p., 50 mu g/d) or mmTGF beta 2-7m (10 mg/d delivered by osmotic pumps) alone or in combination with alpha-PD-L1 Abs (7x i.p. of 100 mu g/72 h). Tumor progression and body weight were monitored. Levels of bioactive TGF beta in serum were quantified using a TGF beta bioassay. Tissues were analyzed by immunohistology and flow cytometry. Therapy with mRER or mmTGF beta 2-7m reduced tumor burden (P < 0.05) and decreased body weight loss compared with controls. In inhibitor-treated mice, levels of TGF beta in tumor tissue and serum were reduced (P < 0.05), whereas they increased with tumor progression in controls. Both inhibitors enhanced CD8(+) T-cell infiltration into tumors and mRER reduced levels of myeloid-derived suppressor cells (P < 0.001). In combination with alpha-PD-L1 Abs, tumor burden was not further reduced; however, mmTGF beta 2-7m further reduced weight loss (P < 0.05). The collagen-rich stroma was reduced by using combinatorial TGF beta/PD-L1 therapies (P < 0.05), enabling an accelerated lymphocyte infiltration into tumor tissues. The blockade of TGF beta signaling by mRER or mmTGF beta 2-7m ameliorated in vivo progression of established murine OSCC. The inhibitors promoted antitumor immune responses, alone and in combination with alpha-PD-L1 Abs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available